Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)
China · Delayed Price · Currency is CNY 26.81
-0.05 (-0.19%)
At close: Feb 13, 2026
Wuhan Hvsen Biotechnology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,606 | 1,139 | 966.95 | 934.11 | 964.74 | 739.79 |
Other Revenue | 61.09 | 61.09 | 52.81 | 88.79 | 31.48 | 37.67 |
| 1,667 | 1,200 | 1,020 | 1,023 | 996.22 | 777.46 | |
Revenue Growth (YoY) | 48.74% | 17.71% | -0.31% | 2.68% | 28.14% | 81.98% |
Cost of Revenue | 1,233 | 1,006 | 809.11 | 800.16 | 727.71 | 491.59 |
Gross Profit | 434.22 | 194.72 | 210.65 | 222.75 | 268.51 | 285.87 |
Selling, General & Admin | 126.22 | 118.74 | 131.31 | 101.98 | 88.49 | 85.88 |
Research & Development | 70.87 | 55.8 | 44.6 | 40.14 | 46.89 | 28.38 |
Other Operating Expenses | -2.01 | 3.52 | 3.23 | 8.84 | 4.92 | 4.41 |
Operating Expenses | 201.57 | 176.37 | 204.08 | 161.73 | 133.23 | 123.43 |
Operating Income | 232.65 | 18.35 | 6.57 | 61.01 | 135.28 | 162.43 |
Interest Expense | -20.6 | -42.66 | -28.22 | -18.38 | -2.87 | -2.3 |
Interest & Investment Income | 7.75 | 10.03 | 17.47 | 10.31 | 10.54 | 6.75 |
Currency Exchange Gain (Loss) | 0.69 | 0.69 | -0.16 | -0.03 | -0.03 | -0.04 |
Other Non Operating Income (Expenses) | -3.14 | -1.35 | -0.62 | -0.67 | -0.47 | -0.38 |
EBT Excluding Unusual Items | 217.35 | -14.96 | -4.95 | 52.24 | 142.45 | 166.47 |
Gain (Loss) on Sale of Investments | 20.19 | -23.64 | 12.25 | 1.46 | 1.55 | 0.63 |
Gain (Loss) on Sale of Assets | - | - | - | 0.01 | -0.06 | - |
Asset Writedown | -0.34 | - | - | - | - | -0.41 |
Other Unusual Items | 9.62 | 9.62 | 5.14 | 3 | 6.89 | 9.34 |
Pretax Income | 246.82 | -28.97 | 12.44 | 56.71 | 150.83 | 176.03 |
Income Tax Expense | 30.49 | -9.2 | -4.34 | 4 | 17.97 | 25.88 |
Earnings From Continuing Operations | 216.33 | -19.77 | 16.78 | 52.71 | 132.87 | 150.16 |
Minority Interest in Earnings | -0.92 | -0.38 | - | - | - | - |
Net Income | 215.41 | -20.16 | 16.78 | 52.71 | 132.87 | 150.16 |
Net Income to Common | 215.41 | -20.16 | 16.78 | 52.71 | 132.87 | 150.16 |
Net Income Growth | - | - | -68.16% | -60.33% | -11.52% | 118.36% |
Shares Outstanding (Basic) | 181 | 166 | 166 | 165 | 166 | 147 |
Shares Outstanding (Diluted) | 181 | 166 | 166 | 165 | 166 | 147 |
Shares Change (YoY) | 8.54% | -0.06% | 0.33% | -0.19% | 12.59% | 18.45% |
EPS (Basic) | 1.19 | -0.12 | 0.10 | 0.32 | 0.80 | 1.02 |
EPS (Diluted) | 1.19 | -0.12 | 0.10 | 0.32 | 0.80 | 1.02 |
EPS Growth | - | - | -68.27% | -60.25% | -21.41% | 84.35% |
Free Cash Flow | 121.46 | -150.89 | -91.39 | -332.18 | -444.4 | -182.49 |
Free Cash Flow Per Share | 0.67 | -0.91 | -0.55 | -2.01 | -2.68 | -1.24 |
Dividend Per Share | 0.206 | 0.106 | 0.270 | 0.300 | 0.331 | 0.273 |
Dividend Growth | -23.55% | -60.59% | -10.00% | -9.37% | 21.11% | - |
Gross Margin | 26.04% | 16.22% | 20.66% | 21.78% | 26.95% | 36.77% |
Operating Margin | 13.95% | 1.53% | 0.64% | 5.96% | 13.58% | 20.89% |
Profit Margin | 12.92% | -1.68% | 1.65% | 5.15% | 13.34% | 19.31% |
Free Cash Flow Margin | 7.29% | -12.57% | -8.96% | -32.48% | -44.61% | -23.47% |
EBITDA | 340.34 | 131.48 | 126.96 | 123.58 | 163.82 | 181.52 |
EBITDA Margin | 20.41% | 10.95% | 12.45% | 12.08% | 16.44% | 23.35% |
D&A For EBITDA | 107.69 | 113.13 | 120.39 | 62.57 | 28.54 | 19.08 |
EBIT | 232.65 | 18.35 | 6.57 | 61.01 | 135.28 | 162.43 |
EBIT Margin | 13.95% | 1.53% | 0.64% | 5.96% | 13.58% | 20.89% |
Effective Tax Rate | 12.35% | - | - | 7.06% | 11.91% | 14.70% |
Revenue as Reported | 1,667 | 1,200 | 1,020 | 2,046 | 996.22 | 777.46 |
Advertising Expenses | - | 6.83 | 6.78 | 3.2 | 1.71 | 3.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.